RxDoctor Payments DataLook up a doctor →

Janelle Meyer, MD

Hematology & Oncology · Salem, ORNPI 1881720068

Payments from drug & device makers

$1,583,877in general payments, 2019–2025

Across 401 payments — averaging $3949.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Genentech, Inc.$465K
  • Novartis$349K
  • AbbVie$210K
  • AstraZeneca$137K
  • Mirati Therapeutics, Inc.$132K
  • Janssen Research & Development, LLC$124K
  • plus $168K from 54 others
$796in research payments, 2019–2025

Across 1 payment — averaging $796.35 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$796

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Genentech, Inc.30$465,038
Novartis22$349,494
AbbVie34$209,506
AstraZeneca(2 entities)31$136,646
Mirati Therapeutics, Inc.22$131,985
Janssen Research & Development, LLC35$123,619
Taiho Oncology, Inc.41$86,644
Otsuka Pharmaceutical Co., Ltd.3$41,829
Eli Lilly5$21,902
Gilead5$9,759
Astrazeneca UK Limited1$3,600
Johnson & Johnson15$348
Astellas Pharma US Inc10$322
Pfizer17$299
Merck14$293
GSK6$150
Eisai Inc.6$143
Sanofi5$139
E.r. Squibb & Sons, L.L.C.5$130
Daiichi Sankyo Inc.6$122
Bristol Myers Squibb4$115
Incyte Corporation6$114
Regeneron Healthcare Solutions, Inc.4$113
Pharmacyclics LLC, An Abbvie Company4$92
Amgen4$92
Genentech USA, Inc.3$89
Kyowa Kirin, Inc.4$76
Exelixis Inc.3$69
Tersera Therapeutics LLC3$63
Takeda Pharmaceuticals U.S.A., Inc.4$62
Puma Biotechnology, Inc.3$57
Genmab U.S., Inc.2$55
Ipsen Biopharmaceuticals, Inc3$55
Apellis Pharmaceuticals, Inc.2$52
Organon2$50
Pharmacosmos Therapeutics Inc.2$49
Beone Medicines USA, Inc.2$45
EMD Serono, Inc.2$45
Springworks Therapeutics, Inc.1$43
Jazz Pharmaceuticals Inc.2$41
Seagen Inc.2$41
Verity Pharmaceuticals Inc.2$39
Tesaro, Inc.2$37
Stemline Therapeutics Inc.1$35
Acrotech Biopharma Inc.2$34
Immunocore Limited1$34
AVEO Pharmaceuticals, Inc.2$29
Bayer2$26
Foundation Medicine, Inc.1$24
Clovis Oncology, Inc.1$23
ADC Therapeutics America, Inc.1$22
Deciphera Pharmaceuticals Inc.1$21
Agios Pharmaceuticals, Inc.1$19
Pharmaessentia USA Corporation1$18
Adaptive Biotechnologies Corporation1$18
Servier Pharmaceuticals LLC1$18
Array Biopharma Inc1$17
Helsinn Therapeutics (U.S.), Inc.1$17
Blueprint Medicines Corporation1$15
Coherus Oncology, Inc.1$15

How this compares

$1,583,877 in reported general payments places this provider in the 85th percentile of 112 hematology & oncology providers in Oregon.

See all hematology & oncology providers in Oregon →

Medicare billing

Part B allowed, 2024
$1,092,946
Medicare patients
288
Services billed
61,083

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other hematology & oncology in Salem

See the full list for Oregon →

Where these figures come from

Is this you, or does something look wrong? →